Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: Insights from the switching anti-platelet (SWAP) study
Jorge F. Saucedo
1
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
,
Dominick J. Angiolillo
2
University of Florida College of Medicine - Jacksonville, Jacksonville, Florida, USA
,
Roger DeRaad
3
Black Hills Clinical Research Center, Rapid City, South Dakota, USA
,
Andrew L. Frelinger III
4
Children’s Hospital Boston, Harvard Medical School, Boston, Massachusetts, USA
,
Paul A. Gurbel
5
Sinai Center for Thrombosis Research, Baltimore, Maryland, USA
,
Timothy M. Costigan
6
Eli Lilly and Company or a subsidiary, Indianapolis, Indiana, USA
,
Joseph A. Jakubowski
6
Eli Lilly and Company or a subsidiary, Indianapolis, Indiana, USA
,
Clement K. Ojeh
6
Eli Lilly and Company or a subsidiary, Indianapolis, Indiana, USA
,
Suman Duvvuru
6
Eli Lilly and Company or a subsidiary, Indianapolis, Indiana, USA
,
Mark B. Effron
6
Eli Lilly and Company or a subsidiary, Indianapolis, Indiana, USA